Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 71Thoracic 30Breast 29Head & Neck 23Genitourinary 16CNS 15Sarcoma 14Gynecologic 14Dermatologic 11Other solid neoplasm 9Other neoplasm 5Other hematologic neoplasm 4Lymphoid 4Tumor-Agnostic 3Plasma cell 3Myeloid 3Other 1Endocrine 1Classical hematology 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Celecoxib × Tumor-Agnostic × Clear all
NCT03864575 2019-07-12

NICE-COMBO

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 2 Unknown
68 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00596219 2015-12-23

Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma

Memorial Sloan Kettering Cancer Center

Phase NA Completed
12 enrolled
Tumor-Agnostic

Carcinoma, Carcinoma, Squamous Cell

NCT00165451 2011-07-07

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
20 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡